Compare Heron Therapeutics Inc (HRTX) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Sony Group Corp — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Sony Group Corp trades at $24.09 (market cap $138.06B). The key difference: Sony Group Corp is far larger — about 1864.7× Heron Therapeutics Inc's market cap, and Sony Group Corp pays a 0.67% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Sony Group Corp for 96 Days on average.
| HRTX | SONY | |
|---|---|---|
Market Cap | $74.04M | $138.06B |
Volume | 3,668,095 | 3,986,731 |
Sector | Health | Technology |
52-Week High | $1.49 | $30.26 |
52-Week Low | $0.27 | $19.32 |
Typical Hold Time | 35 Days | 96 Days |
Enterprise Value | $180.78M | $135.96B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Sony trades at $23.95, up 0.42% with neutral technical signals. The company shows strong cash flow generation ($2.32T operating cash flow in 2025) and beat earnings expectations in two of the last three quarters. However, 2026 projections indicate potential challenges with negative net income margin and declining revenue. Analyst sentiment remains positive with 11 buy ratings and no sell recommendations among 16 analysts covering the stock.
Sony presents a mixed investment case with solid entertainment assets and cash flow strength offset by near-term profitability concerns. The stock's reasonable valuation (P/E 19.93, P/S 1.75) and strong analyst support provide upside potential, but investors must monitor execution against 2026 guidance and competitive pressures in entertainment markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
